共 50 条
Synthesis and biological evaluation of santacruzamate A and analogs as potential anticancer agents
被引:9
|作者:
Liu, Qi
[1
,2
]
Lu, Wenhua
[1
]
Ma, Mingzhe
[1
]
Liao, Jianwei
[1
]
Ganesan, A.
[3
]
Hu, Yumin
[1
]
Wen, Shijun
[1
,2
]
Huang, Peng
[1
]
机构:
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[3] Univ E Anglia, Sch Pharm, Norwich NR4 7TJ, Norfolk, England
来源:
关键词:
HISTONE DEACETYLASE INHIBITORS;
CANCER-CELLS;
MULTIDRUG-RESISTANCE;
DERIVATIVES;
ANTITUMOR;
THIOUREA;
MODULATORS;
DESIGN;
DRUGS;
ROS;
D O I:
10.1039/c4ra13889a
中图分类号:
O6 [化学];
学科分类号:
0703 ;
摘要:
Santacruzamate A, a recently discovered natural product from a Panamanian marine cyanobacterium Symploca sp., features a similar structure to the clinically used histone deacetylase (HDAC) inhibitor vorinostat (SAHA). We have synthesized the natural product and a small set of analogues for SAR studies. To our surprise, the synthetic natural product santacruzamate A (1a) and the analogues did not show an obvious inhibition even at 2 mu M in HDAC enzyme assays while the IC50 value was 0.12 nM in the original report. However, a novel compound, 5, containing a terminal thiourea motif was found to inhibit the growth of malignant cells at submicromolar concentrations. Moreover, 5 was not cytotoxic to normal human colonic epithelial cells CCD841, suggesting that its cytotoxicity was specific to cancer cells. Further investigation indicated that the compound induced apoptosis, affected cell cycle progression and increased ROS production. We believe its mechanism of action is unrelated to HDAC inhibition and the original activity reported for santacruzamate needs to be reevaluated.
引用
收藏
页码:1109 / 1112
页数:4
相关论文